-
1
The global burden of inflammatory bowel disease (IBD) is increasing, affecting both high-income and low- and middle-income countries.
-
2
Patients in low- and middle-income countries face significant barriers, including shortages of specialists and limited access to advanced therapies.
-
3
Disadvantaged groups in high-income countries encounter financial barriers and are often diagnosed late, impacting their treatment outcomes.
-
4
Equitable IBD care requires addressing geographic, socioeconomic, and cultural disparities to ensure all patients achieve comparable health outcomes.
-
5
Future strategies must involve policy reforms, expanded diagnostic capacity, and community engagement to improve access to IBD care globally.
